Avanti il prossimo

Riproduzione automatica

Immunosuppressive therapy in myelodysplastic syndrome

12 Visualizzazioni • 07/04/23
Condividere
Incorporare
administrator
administrator
Iscritti
0

Dr Stahl speaks with ecancer at the 2017 ASH annual meeting about the use of immunosuppressive therapy in patients with the myelodysplastic syndromes.

He outlines biomarkers assessed in the hopes of finding predictive factors for patient response, noting that only SF3B1 mutations were validated, negatively affecting response to IST.

Dr Stahl also describes differences in overall survival for patients achieving an objective response.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Mostra di più
0 Commenti sort Ordina per
Commenti su Facebook

Avanti il prossimo

Riproduzione automatica